Tarsus Pharma Reports Officer Changes & Comp Arrangements
Ticker: TARS · Form: 8-K · Filed: Jan 18, 2024 · CIK: 1819790
| Field | Detail |
|---|---|
| Company | Tarsus Pharmaceuticals, Inc. (TARS) |
| Form Type | 8-K |
| Filed Date | Jan 18, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**Tarsus Pharma just filed an 8-K about executive changes and pay, watch for strategic shifts.**
AI Summary
Tarsus Pharmaceuticals, Inc. filed an 8-K on January 18, 2024, reporting an event that occurred on January 11, 2024, related to the departure or appointment of officers and their compensation. This filing indicates changes in key personnel or their pay structures, which could signal strategic shifts or efforts to retain talent. For investors, understanding these changes is crucial as executive leadership and compensation directly influence a company's direction, operational efficiency, and financial health, potentially impacting future stock performance.
Why It Matters
Changes in executive leadership or their compensation can signal strategic shifts or efforts to retain key talent, directly impacting a company's future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in executive leadership can introduce uncertainty, but the specific details of this filing are not yet public, making the impact unclear.
Analyst Insight
Investors should monitor Tarsus Pharmaceuticals' subsequent filings or press releases for specific details regarding the executive changes and compensation arrangements, as these will provide clarity on potential strategic shifts and their impact on the company's future.
Key Numbers
- 001-39614 — Commission File Number (identifies Tarsus Pharmaceuticals, Inc.'s registration with the SEC)
- 81-4717861 — I.R.S. Employer Identification No. (identifies Tarsus Pharmaceuticals, Inc. for tax purposes)
- $0.0001 — par value per share (the nominal value of Tarsus Pharmaceuticals, Inc.'s Common Stock)
Key Players & Entities
- Tarsus Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
- Delaware (company) — state of incorporation for Tarsus Pharmaceuticals, Inc.
- The Nasdaq Stock Market LLC (company) — exchange where Tarsus Pharmaceuticals, Inc. Common Stock is registered
Forward-Looking Statements
- Tarsus Pharmaceuticals will announce specific details of the officer changes and compensatory arrangements. (Tarsus Pharmaceuticals, Inc.) — high confidence, target: Q1 2024
- The market will react to the specific details of the officer changes once they are fully disclosed. (TARS stock price) — medium confidence, target: Q1 2024
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 11, 2024.
What is the primary item information disclosed in this 8-K?
The primary item information disclosed is related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers'.
What is the trading symbol for Tarsus Pharmaceuticals, Inc. on The Nasdaq Stock Market LLC?
The trading symbol for Tarsus Pharmaceuticals, Inc. on The Nasdaq Stock Market LLC is TARS.
Is Tarsus Pharmaceuticals, Inc. considered an emerging growth company?
Yes, Tarsus Pharmaceuticals, Inc. has indicated by check mark that it is an emerging growth company.
What is the business address of Tarsus Pharmaceuticals, Inc. as stated in the filing?
The business address of Tarsus Pharmaceuticals, Inc. is 15440 Laguna Canyon Road, Suite 160, Irvine, CA 92618.
Filing Stats: 471 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-01-18 16:30:29
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share TARS The Nasdaq Sto
Filing Documents
- tars-20240111.htm (8-K) — 23KB
- 0001819790-24-000006.txt ( ) — 149KB
- tars-20240111.xsd (EX-101.SCH) — 2KB
- tars-20240111_lab.xml (EX-101.LAB) — 24KB
- tars-20240111_pre.xml (EX-101.PRE) — 13KB
- tars-20240111_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TARSUS PHARMACEUTICALS, INC. Date: January 18, 2024 /s/ Jeffrey S. Farrow Jeffrey S. Farrow Chief Financial Officer and Chief Strategy Officer (Principal Financial Officer and Principal Accounting Officer)